Wells Fargo Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) but lowered the price target from $90 to $84.
February 07, 2024 | 3:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Gilead Sciences but lowered the price target from $90 to $84.
The reduction in price target by Wells Fargo, despite maintaining the Equal-Weight rating, could lead to a negative short-term sentiment among investors, potentially causing a decrease in Gilead Sciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100